IL33 and immunoglobulin G4-related sclerosing disease: Thus, biologics targeting IFN-I and IL-33 may be promising therapeutics in patients with AIP and IgG4-RD, as evidenced by the results of animal studies, in which the neutralization of IFN-I or IL-33-mediated signaling pathways by Abs efficiently prevented the development of experimental AIP.